Series
Radiotherapy
Status
Published
Date
Number of report
029
Proton Therapy
Ask the expert
The report presents a summary of reimbursement situation for proton therapy in European countries.
The analysis covers the application of proton therapy in ocular tumors in adults and pediatric medulloblastoma.
The analysis is provided for the session and out-patient treatment, including both preparation and delivery of proton therapy. The only reimbursement within public / statutory health insurance systems is considered.
The report includes essential information about reimbursement, including:
- Brief country-specific overview of reimbursement system
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions on indications or scenarios for the use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- Austria
- Belgium
- Denmark
- England (UK)
- Finland
- France
- Germany
- Italy
- The Netherlands
- Norway
- Sweden
- Switzerland
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of equipment for proton therapy include:
- Hitachi Medical Systems (PROBEAT-RT)
- IBA (Proteus ONE, Proteus Plus)
- Mevion (MEVION S250)
- Sumitomo Heavy Industries (HM series)
- Varian Medical Systems (ProBeam, ProBeam Compact, ProBeam Multi-Room)
Table of content
1. Introduction and summary
2. Executive summary table
3. Contents
4. Abbreviations
5. What’s new
6. Methodology
7. Reimbursement analysis in Austria
7.1. Overview of the reimbursement system
7.2. Reimbursement for proton therapy
7.2.1. Policy considerations
7.2.2.1. Health technology assessments by LBI-HTA
8. Reimbursement analysis in Belgium
8.1. Overview of the reimbursement system
8.2. Reimbursement for proton therapy
8.2.1. Procedure coding
8.2.2. Policy considerations by the INAMI/RIZIV
8.2.3.1. Health technology assessments by KCE
9. Reimbursement analysis in Denmark
9.1. Overview of the proton therapy
9.2. Reimbursement for intensity modulated radiotherapy
10. Reimbursement analysis in England
10.1. Overview of the reimbursement system
10.2. Reimbursement for proton therapy
10.2.1. Commissioning of proton therapy
10.2.2. Health technology assessments by NICE
11. Reimbursement analysis in Finland
11.1. Overview of the reimbursement system
11.2. Reimbursement for proton therapy
12. Reimbursement analysis in France
12.1. Overview of the reimbursement system
12.2. Reimbursement for proton therapy
12.2.1. Procedure coding
12.2.2. Diagnosis coding
12.2.3. Payment mechanism and reimbursement tariffs
12.2.4. Policy considerations by HAS
13. Reimbursement analysis in Germany
13.1. Overview of the reimbursement system
13.2. Reimbursement for proton therapy
13.2.1. Procedure coding
13.2.2. Diagnosis coding
13.2.3. Payment mechanism and reimbursement tariffs
13.2.4. Policy considerations by G-BA
14. Reimbursement analysis in Italy
14.1. Overview of the reimbursement system
14.2. Reimbursement for proton therapy
14.2.1. Procedure coding
14.2.2. Payment mechanism and reimbursement tariffs
14.2.3. Policy considerations
15. Reimbursement analysis in the Netherlands
15.1. Overview of the reimbursement system
15.2. Reimbursement for proton therapy
15.2.1. Procedure coding
15.2.2. Payment mechanism and reimbursement tariffs
15.2.3. Policy considerations by Dutch Healthcare Institute (ZIN)
16. Reimbursement analysis in Norway
16.1. Overview of the reimbursement system
16.2. Reimbursement for proton therapy
16.2.1. Procedure coding
16.2.2. Diagnosis coding
16.2.3. Payment mechanism and reimbursement tariffs
16.2.4. Policy considerations
17. Reimbursement analysis in Sweden
17.1. Overview of the reimbursement system
17.2. Reimbursement for proton therapy
17.2.1. Procedure coding
17.2.2. Diagnosis coding
17.2.3. Payment mechanism and reimbursement tariffs
17.2.4. Policy considerations
18. Reimbursement analysis in Switzerland
18.1. Overview of the reimbursement system
18.2. Reimbursement for proton therapy
18.2.1. Procedure coding
18.2.2. Diagnosis coding
18.2.3. Payment mechanism and reimbursement tariffs
18.2.4. Policy considerations
19. Summary of procedure codes
20. Summary of reimbursement codes and tariffs
21. Disclaimer
24
Feb 2022
On January 18, 2022, the Ministry of Health has awarded the Framework Agreement for the acquisition of 81 linear accelerators included in the High-End Technology Equipment Investment Plan. Furthermore, the National Institute of Health Management (INGESA) has also initiated the processing of the Framework Agreement that will facilitate the acquisition of the equipment in the fields of interventional cardiology, interventional vascular radiology, interventional neurovascular, digital brachytherapy, computed tomography, magnetic resonance imaging, PET-CT, SPECT-CT.
Read more22
Feb 2022
In late January 2022, 19 new procedure codes were introduced by the Code Service of the Finnish National Health and Wellbeing Institution (THL). The introduced codes are dedicated to diagnostic imaging and image-guided interventions.
Read more18
Feb 2022
Dutch Organization for Health Research and Development, ZonMw awarded eight projects under the "Healthcare Evaluation and Appropriate Use" program, including two projects for geriatric care, two projects for cancer, per one project for cardiovascular, neurovascular, and dermatology care.
Read more01
Nov 2021
The revised EBM (German Uniform Evaluation Standard) catalog came into force on October 1, 2021. The most significant changes concern mainly IVD tests: extension of the newborn screening, the introduction of microsatellite instability testing, amendments of Oncotype DX® test reimbursement, the introduction of screening for hepatitis B and C as part of health check-up, as well as changes in reimbursement of radiation therapy services.
Read more30
Sep 2021
At the beginning of September 2021, the Government of the Russian Federation released the preliminary version of the Program of State Guarantees for the period of 2022-2024. Major changes concerned the High-End Medical Care (HEMC) list I, where two new procedures in the cardiovascular and neurovascular field were added. The HEMC list II was expanded with the procedures in the field of radiotherapy, neurology, and neurosurgery, surgical procedures. The final version is expected at the beginning of 2022.
Read more